🔴 Neurosense Therapeutics is trading 11.56% down today amid Canadian filing delay to March 2027

Neurosense Therapeutics is trading at $1.76, down 11.56%, amid a delay in its planned Canadian ALS filing to March 2027.

• New PrimeC biomarker data included an NfL analysis showing a greater reduction among treated participants than placebo.
• The filing target moved from December 2026 to March 2027; Health Canada reportedly has no concerns with the revised timing.
• Broader markets were higher. Available reporting does not directly confirm the delay caused the decline.